Where does Janssen Biotech, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Janssen Biotech, Inc. ranks #1,224 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Janssen Biotech, Inc. hold?

Janssen Biotech, Inc. holds 347 US utility patents granted between 2015 and 2025, spanning 30 technology areas.

What is Janssen Biotech, Inc.'s Innovation Score?

Janssen Biotech, Inc. has an Innovation Score of 57.6 out of 100 (top 5% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Janssen Biotech, Inc. focus on?

Janssen Biotech, Inc.'s top technology area is C07K (Peptides) with 247 patents. Grants appear in 30 CPC subclasses total.

Is Janssen Biotech, Inc.'s patent grant rate increasing or decreasing?

Janssen Biotech, Inc.'s recent grant velocity is +28% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Janssen Biotech, Inc.'s patents?

Janssen Biotech, Inc.'s patents average 17.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Janssen Biotech, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Janssen Biotech, Inc.

USPTO PatentsView assignee record - 347 granted patents across 30 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Janssen ranks #1,224 of 49,997 tracked US assignees by granted-patent volume, with 347 patents across 30 technology areas.

#1,224
of 49,997 US assignees by volume: Top 5%
by Innovation Score (57.6/100): 17.6
avg claims per patent: +28%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1224 · US Corporation #1,224 · 347 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-MID 347 grants
TOP-DECILE #1,224/49,997
PHOTO-FINISH King Slide Technology
CPC-FOCUS C07K · 30 areas
INNOV-PAR 57.6/100
CLAIMS-RICH 17.6 claims/avg
TYPE-USCORP US Corporation
VEL-UP +28% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: King Slide Technology Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Aputure Imaging… · near

58
Janssen Biotech · this assignee

58
Linde · near

58
Promerus · near

58
S C Johnson & SON · near

58
3D Lighting… · lowest

7

What this shows Janssen's Innovation Score is 57.6/100 (top 5% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Janssen's grants concentrate

Janssen Biotech, Inc. is a focused PatentsView assignee: 30 CPC subclasses with 71.2% of grants classified under C07K (Peptides). Peak complete grant year is 2024 (56 grants) versus a trough of 22 in 2016. By volume, Janssen sits between Emerson Electric Co. and Cognex Corporation.

Janssen's three-year grant acceleration

From 2019–2021 to 2022–2024, Janssen Biotech, Inc. moved from 100 to 111 grants (1.11x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #940. See the growth leaderboard.

Emerson Electric

349
Razer (Asia-pacif…

349
Mimaki Engineering

348
SK On

348
King Slide Techno…

347
Tusimple

347
Janssen Biotech ◀

347
Aisan Kogyo

346
Cognex

346

What this shows Janssen holds 347 patents at rank #1,224, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #1,224 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Janssen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Janssen, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (58 here).

Linde GmbH 58 S. C. Johnson & SON, Inc. 58 Promerus, LLC 58 Aputure Imaging Industries Co., Ltd. 58

Similar claim depth

Nearest assignees by average claims per patent (17.6 here).

VIA Technologies, Inc. 17.6 avg Cfph, LLC 17.6 avg NEW York University 17.6 avg Fastly, Inc. 17.6 avg

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

58 Top 5% higher than 95% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Janssen Biotech, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	29	8.4%
2016	22	6.3%
2017	29	8.4%
2018	26	7.5%
2019	33	9.5%
2020	30	8.6%
2021	37	10.7%
2022	25	7.2%
2023	30	8.6%
2024	56	16.1%
2025partial year	30	8.6%

Which technologies does Janssen Biotech, Inc. patent most?

C07K - Peptides 247

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 234

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 229

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 96

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 48

Y02A - Technologies FOR Adaptation TO Climate Change 19

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 13

C12Y - Enzymes 13

C07D - Heterocyclic Compounds 10

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 10

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 9

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 9

B01D - Separation 5

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 4

A61F - Filters Implantable Into Blood VESSELS; PROSTHESES; Devices Providing Patency TO, OR Preventing Collapsing OF, Tubular Structures OF THE Body, e.g. STENTS; Orthopaedic, Nursing OR Contraceptive DEVICES; FOMENTATION; Treatment OR Protection OF Eyes OR EARS; Bandages, Dressings OR Absorbent PADS; Firs 3

Top 15 of 30 technology areas

Where it ranks

Overall rank by patents

#1,224

of 49,997 tracked assignees

Innovation Score

57.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Janssen Biotech, Inc.'s patent record in context - here's where to go next.

Janssen Biotech, Inc.'s lead technology class is C07K (Peptides), 71.2% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #1,224 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Janssen Biotech, Inc. against Emerson Electric Co., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 57.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.